BioSpeedia is a biotechnology company founded by two scientific researchers from Institut Pasteur.

We develop and manufacture a portfolio of innovative in vitro diagnostics rapid test kits for medical professionals and clinical diagnostic markets worldwide.

About Us

Established in 2011, BioSpeedia develops and manufactures a portfolio of innovative in vitro diagnostics (IVD) rapid test kits and ELISA kits for medical professionals and clinical diagnostic markets worldwide.

CE marked COVID-19 rapid test kit;

US FDA submission number: EUA202012.

COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples. It is intended to be used for the detection of SARS-CoV-2 virus infection. This protocol can be carried out in 15 minutes (certain results can be read in 3 minutes), and is simple in its implementation.

Our Rapid Antigen Test Kit is expected to launch in Oct-Nov 2020. This is an immunochromatographic assay designed for the qualitative detection of specific SARS-CoV-2 antigen in human nasopharyngeal swab specimen.

World Health Organization (WHO) approved CSF test for meningitis

MeningoSpeed provides an immediate, easy to use and accurate rapid method for the diagnosis of N. meningitidis. The test can be completed in a few minutes as opposed to the current gold standard which can take 48 – 72 hours turnaround time, and up to a week more for serotyping.